降糖方案和循环内皮祖细胞数量的关系

Abstract
Figure/Table
References (0)
Related Citation (0)

Download: PDF (1294 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the effects of different hypoglycemic programme on the influence of the number of circulating endothelial progenitor cells (EPCs) in patients with primary type 2 diabetes. Methods: Forty-five newly diagnosed type 2 diabetes hospitalized patients were selected through the inclusion and exclusion criteria. The age, gender, height, weight, waist circumference and calculated body mass index (BMI) were recorded for each patient. The level of fasting blood glucose (FPG), fasting insulin (FINS), 2 hour postprandial blood glucose (PPG), glycosylated hemoglobin (HbA1c), triglyceride (TG), cholesterol (TC), high density lipoprotein (HDL) and low density lipoprotein (LDL) were measured. The newly diagnosed type 2 diabetes mellitus patients (mentioned above) were randomly divided into three groups according to the different hypoglycemic treatment. group A (n=15): patients were treated with twice per day of premixed insulin therapy (Humalog 25 pin) after 2 weeks of subcutaneous insulin pump therapy (CSII insulin aspart). group B (n=15): patients were treated with oral hypoglycemic drug (Diamicron MR 30-120 mg/d); group C (n=15): patients were treated with premixed insulin (Humalog 25 pin twice perday). After determination of general clinical data, the level of EPCs labled with CD34 and KDR double positive before and after 4 weeks of treatment were measured with flow cytometry. The number of EPCs before and after treatment and three groups after 4 weeks treatment were compared to investigate the short-term effects of different hypoglycemic therapy effects of intensive treatment in newly diagnosed type 2 diabetic patients on the number of EPCs. Results: The clinical indexes and the number of EPCs in the A, B, C three groups showed no difference before treatment (P>0.05). However, treatment significantly increased the number of EPCs in A.C groups was higher than B group after 4 weeks treatment. However no difference observed between A and C group. Meanwile, the number of EPCs and HbA1c had obvious negative linear correlation through mulitiple linear regression analysis. Conclusion: Altogether, these results suggest that the insulin strengthening treatment is better for newly diagnosed patients with type 2 diabetes mellitus. This treatment can relief of “glucotoxicity” rapidly and increase the number of EPCs, which may alleviate the endothelial dysfunction induced by diabetes and may prevent or delay the diabetes chronic vascular complication incidence. Meanwile, the level of blood glucose has a direct impact on the number of EPCs in patients of diabetes. Our result is consistant with published reported that the higher HbA1c usually accompany with the less the number of EPCs in diabetes.

Key words： circulating endothelial progenitor cells newly diagnosed type 2 diabetic early intensive insulin therapy oral hypoglycemic drugs

Received: 31 January 2015

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Aiming1
	SHEN Lizhen2
	LI Chaiwei1
	GAO Saisai1

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2015/V45/I10 /748

[1] Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology[J]. Circ Res, 2004,95(4): 343-353.
[2] Hill JM, Zalos G, Halcox JP. et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk [J]. N Engl J Med, 2003, 348(7): 593-600.
[3] 袁红, 陈君柱, 王兴祥. 高糖对外周血内皮祖细胞数量和功能的影响[J]. 解放军医学杂志, 2004, 29(9): 803-806.
[4] 赵力, 王海昌, 尹涛, 等. 高糖对内皮祖细胞功能的损害及胰岛素的影响[J]. 中国病理生理杂志, 2008, 24(4): 688-691.
[5] Fadini GP, Sartore S, Albiero M, et al. Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy[J]. Arterioscler Thromb Vasc Biol, 2006, 26(9): 2140-2146.
[6] Wang CH, Ting MK, Verma S, et al. Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus [J]. Am Heart J, 2006, 152(6): 1051.e1-e8.
[7] Kumar AH, Caplice NM. Clinical potential of adult vascular progenitor cells[J].Arterioscler Thromb Vasc Biol, 2010, 30(6): 1080-1087.
[8] Fadini GP, Avogaro A. Potential manipulation of endothelial progenitor cells in diabetes and its complications[J]. Diabetes Obes Metab, 2010, 12(7): 570-583.
[9] Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEG-FR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors[J]. Blood, 2000, 95(3): 952-958.
[10] Hristov M, Weber C. Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance[J]. J Cell Mol Med, 2004, 8(4): 498-508.
[11] Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis[J]. Science, 1997, 275(5302): 964-967.
[12] Pistrosch F, Herbrig K, Oelschlaegel U, et al. PPARgam-ma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells[J]. Athero-sclerosis, 2005, 183(1): 163-167.
[13] Fadini GP, Boscaro E, Albiero M, et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes:possible role of stromal-derived factor-1 alpha[J]. Diabetes Care, 2010, 33(7): 1607-1609.
[14] Humpert PM, Djuric Z, Zeuge U, et al. Insulin stimulates the clonogenic potential of angiogenic endothelial progenitor cells by IGF-l receptor-dependent signaling[J]. Mol Med, 2008,14 (5-6): 30l-308.
[15] Fadini GP, de Kreutzenberg SV, Mariano V, et al. Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine [J]. Diabetes Obes Metab, 2011, 13(8): 718-725.
[16] 杨吉锋, 陶松桔, 张亚萍, 等. 短期胰岛素泵强化治疗对初诊T2DM患者循环内皮祖细胞水平的影响及其抗炎机制[J]. 中国临床研究, 2011, 24(8): 666-668.
[17] Reinhard H, Jacobsen PK, Lajer M, et al. Multifactorial treatment increases endothelial progenitor cells in patients with type 2 diabetes[J]. Diabetologia, 2010, 53(10): 2129-
2133.
[18] Churdchomjan W, Kheolamai P, Manochantr S, et al. Com parison of endothelial progenitor cell function in type 2 diabetes with good and poor glycemic control[J]. BMC En-docr Disord, 2010, 10: 5.